Inhalation Anesthesia Market Size By Product (Sevoflurane, Desflurane, Isoflurane), By Application (Induction, Maintenance), By End-use (Hospitals, Ambulatory Surgical Centers), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Russia, Poland, Netherlands, Switzerland, Japan, China, India, Australia, South Korea, Indonesia, Malaysia, Thailand, Brazil, Mexico, Argentina, Saudi Arabia, South Africa, UAE), Application Potential, Competitive Market Share & Forecast, 2019 - 2025Inhalation anesthesia market will exceed USD 1.9 billion by 2025; as per a new research report.
Inhalation anesthesia market growth is primarily driven by increasing demand for surgeries owing to rise in prevalence of neurological, respiratory and other chronic diseases. Favorable reimbursement scenario in developed economies for various surgical procedures will surge industry demand over the coming years. Rising R&D investments in inhalation anesthesia industry will considerably upsurge the business size. Moreover, availability of various insurance schemes for affordable and quick surgical procedures will foster inhalation anesthesia industry growth during the forecast period.
Focus of several industry players on development of effective products and enhancing existing products is expected to favor business growth. Moreover, massive technologies are being introduced to discourse different ecological effect of anesthetic gases and rummage them from hospital vents for further recycling. Introduction of several anesthesia recycling systems by companies such as Anesthetic Gas Reclamation LLC to address the environmental concerns will further foster industry growth. However, patent expiration and side effects of inhalation anesthetics may hinder the overall inhalation anesthesia business growth.
Sevoflurane segment accounted for more than 70% revenue share in 2018 and will witness similar growth trend over the coming years. Sevoflurane with or without the addition of nitrous oxide is suitable for inhalation or gas induction and is widely preferred in pediatric patients. Advantages of sevoflurane including non-pungent odor, minimum effect on cerebral blood flow and low blood gas solubility will further increase its adoption, thus accelerating the segmental growth.
Induction segment was valued around USD 250 million in 2018. Different factors influencing induction anesthesia segment include Minimum Alveolar Concentration (MAC), rate of metabolism by kidney/liver, patient’s age, potency and therapeutic index of drug among others will positively impact the segment growth. Also, induction of anesthesia necessitates higher concentration of drug than the amount required for maintenance, thereby surging the market.
Hospitals segment will witness around 5% CAGR during the forecast timeframe. Rising incidence of injuries and surgical procedures will augment segmental growth. Growing number of multispecialty hospital settings to provide corrective treatment for patients will propel business growth. Additionally, cost effective treatment and surgeries provided by different government hospitals in middle-and-low income countries will act as a positive impact rendering factor in the segment growth.
Asia Pacific inhalation anesthesia industry accounted for more than 20% revenue share in 2018 and is assessed to witness significant CAGR by 2025. Rising adoption of advanced technologies for effective assessment and improved patient care will favor regional market growth. Increasing healthcare spending in the region coupled with growing demand for surgical procedures will spur Asia Pacific market.
Some of the notable business players operating in inhalation anesthesia market include Baxter International, Halocarbon Products, Abbvie, Hikma Pharmaceuticals, Piramal, Lunan Pharmaceutical, Fresenius Kabi and Jiangsu Hengrui Medicine. These business players focus on new product launches, mergers, acquisitions and collaborations to maintain their financial stability and sustain market competition. For instance, in May 2016, Piramal partnered with Julphar, a Middle East and Africa based pharmaceutical company for distribution of Sojourn (Sevoflurane) in Saudi Arabia. This partnership enabled company to enhance its geographic reach and broaden customer base.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook